McKesson Board of Directors Releases Findings and Recommendations of Independent Investigation

Investigation was conducted by an independent committee of the Board, and supported by independent counselCommittee makes recommendations to further strengthen […]

McKesson Launches Health Mart Atlas

New Albany, OHIO, April 5, 2018 – McKesson Corporation today announced the launch of Health Mart Atlas, the largest network of […]

McKesson Specialty Health Partners with CoverMyMeds to Deliver Keynote Address at eyeforpharma Philadelphia 2018

The Woodlands, Texas (April 5, 2018) – As a platinum sponsor for the 16th Annual eyeforpharma Philadelphia Summit, McKesson Specialty […]

McKesson Specialty Health and CoverMyMeds Launch ExpressCoverage, an Integrated eServices Platform Designed to Improve the Patient Care Journey

THE WOODLANDS, Texas (April 4, 2018) – ExpressCoverage™ is a new and powerful patient support platform that connects patients, providers, […]

McKesson Specialty Health and CoverMyMeds Launch ExpressCoverage, an Integrated eServices Platform Designed to Improve the Patient Care Journey

THE WOODLANDS, Texas (April 4, 2018) – ExpressCoverage™ is a new and powerful patient support platform that connects patients, providers, […]

McKesson Announces New Initiatives, Launches Foundation to Help Fight Nation’s Opioid Epidemic

SAN FRANCISCO, March 29, 2018 — McKesson Corporation today announced a series of company initiatives to help fight the opioid […]

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.

CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected […]

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.

CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected […]

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.

CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected […]

ERLEADA (apalutamide), the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, available for order at Biologics, Inc.

CARY, N.C. (February 21, 2018) —Biologics, Inc., a McKesson Specialty Health oncology and complex care pharmacy services company, has been selected […]